| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/12/2023 | 265.41% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 09/08/2023 | 265.41% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/28/2023 | 265.41% | HC Wainwright & Co. | → $30 | Initiates Coverage On | → Buy |
| 07/03/2023 | 180.15% | B of A Securities | → $23 | Initiates Coverage On | → Buy |
| 09/19/2022 | 277.59% | HC Wainwright & Co. | → $31 | Assumes | → Buy |
| 05/18/2022 | 119.24% | Piper Sandler | $45 → $18 | Maintains | Overweight |
| 03/24/2022 | 82.7% | SVB Leerink | $25 → $15 | Maintains | Outperform |
| 01/27/2022 | 241.05% | Baird | → $28 | Initiates Coverage On | → Outperform |
| 12/21/2021 | 241.05% | HC Wainwright & Co. | → $28 | Initiates Coverage On | → Buy |
| 11/22/2021 | 448.11% | Ladenburg Thalmann | → $45 | Initiates Coverage On | → Buy |
| 05/04/2021 | 204.51% | SVB Leerink | → $25 | Initiates Coverage On | → Outperform |
| 05/04/2021 | 192.33% | Jefferies | → $24 | Initiates Coverage On | → Buy |
| 05/04/2021 | 448.11% | Piper Sandler | → $45 | Initiates Coverage On | → Overweight |
What is the target price for Reneo Pharmaceuticals (RPHM)?
The latest price target for Reneo Pharmaceuticals (NASDAQ: RPHM) was reported by HC Wainwright & Co. on October 12, 2023. The analyst firm set a price target for $30.00 expecting RPHM to rise to within 12 months (a possible 265.41% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Reneo Pharmaceuticals (RPHM)?
The latest analyst rating for Reneo Pharmaceuticals (NASDAQ: RPHM) was provided by HC Wainwright & Co., and Reneo Pharmaceuticals reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Reneo Pharmaceuticals (RPHM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Reneo Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Reneo Pharmaceuticals was filed on October 12, 2023 so you should expect the next rating to be made available sometime around October 12, 2024.
Is the Analyst Rating Reneo Pharmaceuticals (RPHM) correct?
While ratings are subjective and will change, the latest Reneo Pharmaceuticals (RPHM) rating was a reiterated with a price target of $0.00 to $30.00. The current price Reneo Pharmaceuticals (RPHM) is trading at is $8.21, which is within the analyst's predicted range.